Zeitschrift für Rheumatologie

, Volume 65, Issue 4, pp 279–284 | Cite as

Sklerodermie-assoziierte Autoantikörper – klinische und diagnostische Relevanz

Leitthema

Zusammenfassung

Autoantikörper sind bei der systemischen Sklerose (SSc) und ihren Varianten die bislang bestbekannte immunologische Veränderung. Mehr als 95% der Patienten mit SSc haben antinukleäre oder andere Autoantikörper im Serum. Bei etwa 90% der Patienten mit antinukleären Antikörpern (ANA) finden sich Sklerodermie-assoziierte Autoantikörper, die eine hohe Spezifität für die SSc aufweisen. Diese Antikörper schließen einander gegenseitig weitgehend aus und sind früh und persistierend im Krankheitsverlauf nachweisbar. Durch die Sklerodermie-assoziierten Autoantikörper charakterisierte SSc-Patienten bilden klinisch, genetisch und prognostisch relativ homogene Subgruppen der Erkrankung. Über diese diagnostisch relevanten Autoantikörper hinaus wurden zahlreiche weitere Autoantikörper bei der SSc beschrieben, die jedoch weder SSc-spezifisch noch einander ausschließend vorkommen und deren Antigene erst teilweise charakterisiert sind. Für einige dieser Autoantikörper wird aber verstärkt die noch nicht beantwortete Frage nach einer direkten Beteiligung an der Pathogenese der Erkrankung diskutiert.

Schlüsselwörter

Systemische Sklerose (SSc) Sklerodermie Autoantikörper Diagnostik 

Scleroderma associated autoantibodies – clinical and diagnostic relevance

Abstract

In systemic sclerosis (SSc) and its variants, autoantibodies are the best known immunological aberration. In more than 95% of the patients, antinuclear antibodies or other autoantibodies can be detected. In about 90% of SSc patients with antinuclear antibodies, scleroderma associated autoantibodies highly specific for systemic sclerosis are found. These autoantibodies usually exclude each other in individual patients, and they are detectable early, persisting during the course of the disease. SSc patients characterized by scleroderma associated autoantibodies belong to disease subsets which are relatively homogeneous in clinical, genetic and prognostic terms. Besides these diagnostically relevant autoantibodies, numerous additional ones have also been described. These are neither SSc specific nor mutually exclusive, and their antigens have only been partially characterized. Some, however, are thought to be relevant to the as yet unanswered question of whether autoantibodies are directly involved in SSc pathogenesis.

Keywords

Systemic sclerosis (SSc) Scleroderma Autoantibodies Diagnostics 

Literatur

  1. 1.
    Akimoto S, Ishikawa O, Takagi H, Miyachi Y (1998) Immunological features of patients with primary biliary cirrhosis (PBC) overlapping systemic sclerosis: a comparison with patients with PBC alone. J Gastroenterol Hepatol 13: 897–901PubMedGoogle Scholar
  2. 2.
    Arbuckle MR, McClain MT, Rubertone MV et al. (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526–1533CrossRefPubMedGoogle Scholar
  3. 3.
    Brinckmann J, Hunzelmann N, El Hallous E et al. (2005) Absence of autoantibodies against correctly folded recombinant fibrillin-1 protein in systemic sclerosis patients. Arthritis Res Ther 7: R1221–R1226CrossRefPubMedGoogle Scholar
  4. 4.
    Cepeda EJ, Reveille JD (2004) Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 16: 723–732CrossRefPubMedGoogle Scholar
  5. 5.
    Chizzolini C, Raschi E, Rezzonico R et al. (2002) Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46: 1602–1613CrossRefPubMedGoogle Scholar
  6. 6.
    Chung L, Utz PJ (2004) Antibodies in scleroderma: direct pathogenicity and phenotypic associations. Curr Rheumatol Rep 6: 156–163PubMedGoogle Scholar
  7. 7.
    Conrad K, Mehlhorn J (2000) Diagnostic and prognostic relevance of autoantibodies in uranium miners. Int Arch Allergy Immunol 123: 77–91CrossRefPubMedGoogle Scholar
  8. 8.
    Crilly A, Hamilton J, Clark CJ et al. (2002) Analysis of transforming growth factor beta 1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61: 678–681CrossRefPubMedGoogle Scholar
  9. 9.
    Dick T, Mierau R, Bartz-Bazzanella P et al. (2002) Coexistence of anti-topoisomerase 1 and anti-centromere antibodies in patients with systemic sclerosis. Ann Rheum Dis 61: 121–127CrossRefPubMedGoogle Scholar
  10. 10.
    Dodig TD, Mack KT, Cassarino DF, Clark SH (2001) Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 44: 723–727CrossRefPubMedGoogle Scholar
  11. 11.
    Eaker EY, Kuldau JG, Verne GN et al. (1999) Myenteric neuronal antibodies in scleroderma: passive transfer evokes alterations in intestinal myoelectric activity in a rat model. J Lab Clin Med 133: 551–556CrossRefPubMedGoogle Scholar
  12. 12.
    Fregeau DR, Leung PS, Coppel RL et al. (1988) Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum 31: 386–392PubMedGoogle Scholar
  13. 13.
    Fujimoto M, Sato S (2005) B lymphocytes and systemic sclerosis. Curr Opin Rheumatol 17: 746–751CrossRefPubMedGoogle Scholar
  14. 14.
    Goldblatt F, Gordon TP, Waterman SA (2002) Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 123: 1144–1150CrossRefPubMedGoogle Scholar
  15. 15.
    Greidinger EL, Zang Y, Jaimes K et al. (2006) A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum 54: 661–669CrossRefPubMedGoogle Scholar
  16. 16.
    Hénault J, Robitaille G, Senécal JL, Raymond Y (2006) DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum 54: 963–973CrossRefPubMedGoogle Scholar
  17. 17.
    Hill MB, Phipps JL, Cartwright RJ et al. (1996) Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 106: 491–497CrossRefPubMedGoogle Scholar
  18. 18.
    Howe S, Eaker EY, Sallustio JE et al. (1994) Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 94: 761–770PubMedGoogle Scholar
  19. 19.
    Hu PQ, Fertig N, Medsger TA Jr, Wright TM (2003) Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum 48: 1363–1373CrossRefPubMedGoogle Scholar
  20. 20.
    Johnson RW, Tew MB, Arnett FC (2002) The genetics of systemic sclerosis. Curr Rheumatol Rep 4: 99–107PubMedGoogle Scholar
  21. 21.
    Kallenberg CGM, Wouda AA, Hoet MH, van Venrooij WJ (1988) Development of connective tissue disease in patients presenting with Raynaud’s phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 47: 634–641PubMedGoogle Scholar
  22. 22.
    Kaufman LD, Gruber BL, Marchese MJ, Seibold JR (1989) Anti-IgE autoantibodies in systemic sclerosis (scleroderma). Ann Rheum Dis 48: 201–205PubMedGoogle Scholar
  23. 23.
    Kuwana M, Kaburaki J, Mimori T et al. (2000) Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43: 1074–1084CrossRefPubMedGoogle Scholar
  24. 24.
    Lee EB, Kim JY, Lee YJ et al. (2004) Transforming growth factor-beta1 polymorphisms in Korean patients with systemic sclerosis. Tissue Antigen 63: 491–495CrossRefGoogle Scholar
  25. 25.
    LeRoy EC, Medsger TA (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28: 1573–1576PubMedGoogle Scholar
  26. 26.
    Lunardi C, Bason C, Navone R et al. (2000) Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nature Med 6: 1183–1186CrossRefPubMedGoogle Scholar
  27. 27.
    Maricq HR, Valter I (2004) A working classification of scleroderma spectrum disorders: a proposal and the results of testing on a sample of patients. Clin Exp Rheumatol 22: S5–S13PubMedGoogle Scholar
  28. 28.
    Masi AT, Rodnan GP, Medsger TA et al. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590PubMedGoogle Scholar
  29. 29.
    Mierau R, Genth E (2002) Neue Aspekte der Autoantikörper-Diagnostik bei Kollagenosen. Z Rheumatol 61: 355–366CrossRefPubMedGoogle Scholar
  30. 30.
    Momot T, Koch S, Hunzelmann N et al. (2004) Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum 50: 1561–1565CrossRefPubMedGoogle Scholar
  31. 31.
    Nadashkevich O, Davis P, Fritzler MJ (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 10: CR615–CR621PubMedGoogle Scholar
  32. 32.
    Nielen MMJ, van Schaardenburg D, Reesink HW et al. (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis – A study of serial measurements in blood donors. Arthritis Rheum 50: 380–386CrossRefPubMedGoogle Scholar
  33. 33.
    Nishijima C, Hayakawa I, Matsushita T et al. (2004) Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138: 357–363CrossRefPubMedGoogle Scholar
  34. 34.
    Ohtsuka T, Yamakage A, Yamazaki S (2002) The polymorphism of transforming growth factor-beta1 gene in Japanese patients with systemic sclerosis. Br J Dermatol 147: 458–463CrossRefPubMedGoogle Scholar
  35. 35.
    Rantapää Dahlqvist S, deJong BAW, Berglin E et al. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48: 2741–2749CrossRefPubMedGoogle Scholar
  36. 36.
    Reveille JD, Fischbach M, McNearney T et al. (2001) Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum 30: 332–346CrossRefPubMedGoogle Scholar
  37. 37.
    Sato S, Hamaguchi Y, Hasegawa M, Takehara K (2001) Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatology (Oxford) 40: 1135–1140Google Scholar
  38. 38.
    Sato S, Hayakawa I, Hasegawa M et al. (2003) Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120: 542–547CrossRefPubMedGoogle Scholar
  39. 39.
    Sato H, Lagan AL, Alexopoulou C et al. (2004) The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis Rheum 50: 558–564CrossRefPubMedGoogle Scholar
  40. 40.
    Senécal JL, Hénault J, Raymond Y (2005) The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma). J Rheumatol 32: 1643–1649PubMedGoogle Scholar
  41. 41.
    Sgonc R, Gruschwitz MS, Boeck G et al. (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 43: 2550–2562CrossRefPubMedGoogle Scholar
  42. 42.
    Steen VD (2005) Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35: 35–42CrossRefPubMedGoogle Scholar
  43. 43.
    Sugiura Y, Banno S, Matsumoto Y et al. (2003) Transforming growth factor beta1 gene polymorphism in patients with systemic sclerosis. J Rheumatol 30: 1520–1523PubMedGoogle Scholar
  44. 44.
    Tan FK, Arnett FC, Antohi S et al. (1999) Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 163: 1066–1072PubMedGoogle Scholar
  45. 45.
    Tan FK, Arnett FC, Reveille JD et al. (2000) Autoantibodies to fibrillin 1 in systemic sclerosis – Ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 43: 2464–2471CrossRefPubMedGoogle Scholar
  46. 46.
    Tsuchiya N, Kuroki K, Fujimoto M et al. (2004) Association of a functional CD19 polymorphism with susceptibility to systemic sclerosis. Arthritis Rheum 50: 4002–4007CrossRefPubMedGoogle Scholar
  47. 47.
    Weiner ES, Hildebrandt S, Senécal JL et al. (1991) Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud’s disease. Arthritis Rheum 34: 68–77PubMedGoogle Scholar
  48. 48.
    Zhou X, Tan FK, Milewicz DM et al. (2005) Autoantibodies to fibrillin-1 activate normal human fibroblasts in culture through the TGF-beta pathway to recapitulate the „scleroderma phenotype“. J Immunol 175: 4555–4560PubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Rheumaklinik und Rheumaforschungsinstitut Aachen
  2. 2.Labor an der Rheumaklinik AachenAachen

Personalised recommendations